Besides, through analyzing the dose-response file from the public database, Doris et al. discovered that multiple human cancer cells with high ELF4 expression only showed response to dasatinib, WH-4-023, and ponatinib (all targeting SRC), while being resistant to the majority of anti-cancer agents 46. Here, ELF4 is linked to cancer.